Estimated Annual Spending on Aducanumab in the US Medicare Program

John N Mafi; Mei Leng; Julia Cave Arbanas; Chi-Hong Tseng; Cheryl L Damberg; Catherine Sarkisian; Bruce E Landon

doi:10.1001/jamahealthforum.2021.4495

Estimated Annual Spending on Aducanumab in the US Medicare Program

JAMA Health Forum. 2022 Jan 14;3(1):e214495. doi: 10.1001/jamahealthforum.2021.4495. eCollection 2022 Jan.

Authors

John N Mafi^{1

2}, Mei Leng¹, Julia Cave Arbanas¹, Chi-Hong Tseng¹, Cheryl L Damberg², Catherine Sarkisian^{1

3}, Bruce E Landon^{4

5}

Affiliations

¹ Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
² RAND Corporation, Santa Monica, California.
³ VA Greater Los Angeles Healthcare System, Los Angeles, California.
⁴ Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
⁵ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Abstract

This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Aged
Antibodies, Monoclonal, Humanized
Cognitive Dysfunction* / drug therapy
Cross-Sectional Studies
Dementia*
Humans
Medicare
United States

Substances

Antibodies, Monoclonal, Humanized
aducanumab

Abstract

Publication types

MeSH terms

Substances

Grants and funding